Johnson & Johnson(JNJ -0.69%) announced priority review for its hepatitis C drug simeprevir. In this video, health-care analyst David Williamson discusses the positive aspects of this decision and how a competing drug also angling for approval may actually help boost sales for J&J.
Is Johnson & Johnson's simeprevir destined to be the first next-gen hepatitis-C drug.
David Williamson has no position in any stocks mentioned. Follow David on Twitter @MotleyDavid.
The Motley Fool recommends Gilead Sciences. It recommends and owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.